Renaissance Technologies LLC Increases Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Renaissance Technologies LLC boosted its position in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 31.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,073,500 shares of the company's stock after purchasing an additional 255,600 shares during the period. Renaissance Technologies LLC owned about 0.85% of Organogenesis worth $3,435,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in Organogenesis by 107.8% in the third quarter. JPMorgan Chase & Co. now owns 205,943 shares of the company's stock valued at $589,000 after purchasing an additional 106,823 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Organogenesis by 54.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company's stock valued at $9,443,000 after purchasing an additional 1,035,120 shares during the last quarter. Prudential Financial Inc. lifted its stake in Organogenesis by 92.9% in the fourth quarter. Prudential Financial Inc. now owns 237,720 shares of the company's stock valued at $761,000 after purchasing an additional 114,500 shares during the last quarter. Barclays PLC lifted its position in shares of Organogenesis by 251.7% during the third quarter. Barclays PLC now owns 94,809 shares of the company's stock worth $271,000 after acquiring an additional 67,855 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Organogenesis by 0.6% during the third quarter. State Street Corp now owns 1,459,767 shares of the company's stock worth $4,175,000 after acquiring an additional 9,090 shares in the last quarter. Hedge funds and other institutional investors own 49.57% of the company's stock.

Insider Transactions at Organogenesis

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the sale, the director now owns 166,879 shares of the company's stock, valued at $851,082.90. This trade represents a 13.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 36.90% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley increased their target price on Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th.

Organogenesis Price Performance

Organogenesis stock traded up $0.11 during midday trading on Monday, reaching $4.67. 954,021 shares of the stock were exchanged, compared to its average volume of 1,128,030. The company's fifty day moving average is $4.49 and its 200-day moving average is $3.80. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. Organogenesis Holdings Inc. has a 52 week low of $2.21 and a 52 week high of $6.71. The firm has a market cap of $592.29 million, a PE ratio of -77.83 and a beta of 1.79.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.